Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness

Bin Bao, Asfar S Azmi, Yiwei Li

  • 1Departments of Pathology and Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, 740 HWCRC, 4100 John R Street, Detroit, MI 48201, USA. fsarkar@med.wayne.edu.

Insights

Reactive oxygen species (ROS) are key in cell signaling, but imbalances (oxidative stress) drive cancer. MicroRNAs (miRNAs) and genistein show potential for targeting ROS in cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Reactive oxygen species (ROS) are crucial signaling molecules, but their imbalance (oxidative stress) contributes to cancer development and progression.
  • Oxidative stress damages biomolecules, leading to genomic instability, mutations, and altered gene expression, promoting tumorigenesis.
  • Altered ROS production is linked to cancer stem cells (CSCs), epithelial-to-mesenchymal transition (EMT), and hypoxia, key factors in tumor aggressiveness.

Purpose of the Study:

  • To explore the role of microRNAs (miRNAs) in regulating ROS production during tumorigenesis.
  • To investigate the potential of targeting ROS-mediated pathways involving miRNAs for cancer prevention and treatment.
  • To discuss the anti-tumor effects of genistein in regulating ROS production during tumor development.

Main Methods:

  • Review of experimental studies investigating ROS, oxidative stress, and their impact on cancer.
  • Analysis of emerging evidence on the involvement of miRNAs in ROS regulation and tumorigenesis.
  • Examination of the role of genistein as a potential therapeutic agent targeting ROS.

Main Results:

  • Oxidative stress is strongly associated with increased tumor cell growth, treatment resistance, metastasis, and aggressiveness.
  • Altered ROS production correlates with CSCs, EMT, and hypoxia, though precise mechanisms require further elucidation.
  • Deregulation of miRNAs is linked to altered ROS production, suggesting their regulatory role.

Conclusions:

  • Targeting ROS through miRNA deregulation or natural antioxidants like genistein offers a promising therapeutic strategy for human malignancies.
  • Further research is needed to fully understand the intricate mechanisms of ROS, miRNAs, and hypoxia in cancer.
  • Genistein demonstrates potential as an anti-tumor agent by modulating ROS production in tumorigenesis.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...